05Y Stock Chart & Stats
€1.08
<€0.01(0.43%)
At close: 4:00 PM EDT
€1.08
<€0.01(0.43%)
Day’s Range― - ―
52-Week Range€1.02 - €1.78
Previous CloseN/A
Volume0.00
Average Volume (3M)98.00
Market Cap
€33.46M
Enterprise Value€29.61
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume50
30 Day Avg. Volume98
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oral Small-molecule PlatformAn oral small-molecule platform can support practical development and broader commercial use if clinical efficacy is established. The protease/enzyme focus may also allow the company to extend its discovery capabilities beyond a single indication.
Low Financial LeverageMinimal debt reduces interest and refinancing pressure and leaves fewer creditor claims on the business. Although liquidity remains constrained, the low-leverage structure limits balance-sheet risk relative to a similarly loss-making company with substantial borrowings.
Reduced Annual Loss And Cash BurnThe substantial year-over-year improvement in net loss and operating cash burn indicates progress in controlling spending. If sustained, this could extend financial runway and make future funding requirements more manageable, even though cash generation remains negative.
Bears Say
No Recent Operating RevenueThe absence of recent revenue confirms that the company has not yet established a recurring commercial income base. Its financial outlook therefore depends heavily on clinical progress, licensing or collaboration income, and access to external capital.
Persistent Negative Cash GenerationOngoing negative operating and free cash flow means the current business does not fund its own development activities. Continued reliance on financing or asset contraction increases execution risk and can restrict the company’s ability to advance its pipeline.
Shrinking Equity And Asset BaseThe sharp contraction in equity and total assets reflects cumulative cash burn and materially reduces financial flexibility. A smaller capital base leaves less capacity to absorb development setbacks or fund clinical programs without additional external financing.
Vivoryon Therapeutics AG News
05Y FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.01 and its highest was €1.78 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €33.46M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 88 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went up 2.991%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in DE:05Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.